Private Markets Research and Data, Reimagined

pvtIQ

pvtIQ leverages Smartkarma’s technology and distribution to deliver high-quality research and data on Asian private markets.

Private Markets Analyst, pvtIQ

Beier Luo

Private Markets Analyst

Private Capital Markets

<h2>Executive Summary</h2>
<ul>
<li>
Agentic Workflows Accelerating as Liquidity Thesis Tracks to Plan: The baseline investment theses remain intact, with the transition towards agentic workflows accelerating through dedicated leadership appointments and the proprietary data moat reinforced by new bioactivity datasets. While a confidential dual listing application targeting a US$300.0m to US$400.0m raise supports the liquidity thesis, limited public disclosure of financial reporting and senior leadership continues to introduce execution friction.</li>
<li>
Deepening Biopharma Capabilities and Strategic Artificial Intelligence Investments: The company expanded its life sciences architecture through a strategic data partnership with Evolvus to integrate highly curated therapeutic datasets and appointed veteran product leaders to direct its life sciences strategy and artificial intelligence drafting products. Beyond organic development, participation in the Vertex Ventures-led US$3.0m seed round of the autonomous research platform Drylab AI, and integration with the ASEAN IP Cooperation further reinforce its ecosystem footprint.</li>
<li>
Governance Drags Offset by Strengthening Data Moats: The pvtIQ Fundamental SmartScore© improved, led by Growth and Management after strategic talent acquisitions and a new data partnership, although Governance remains constrained by limited public disclosure of financial reporting and senior leadership. The pvtIQ Alt-Data SmartScore© also strengthened. Strong Product Affinity and Authority dimensions reflect consistent user satisfaction and high search engine visibility, while Socials remains the weakest dimension despite improving.</li>
</ul>

Executive Summary


Agentic Workflows Accelerating as Liquidity Thesis Tracks to Plan: The baseline investment theses remain intact, with the transition towards agentic workflows accelerating through dedicated leadership appointments and the proprietary data moat reinforced by new bioactivity datasets. While a confidential dual listing application targeting a US$300.0m to US$400.0m raise supports the liquidity thesis, limited public disclosure of financial reporting and senior leadership continues to introduce execution friction.

Deepening Biopharma Capabilities and Strategic Artificial Intelligence Investments: The company expanded its life sciences architecture through a strategic data partnership with Evolvus to integrate highly curated therapeutic datasets and appointed veteran product leaders to direct its life sciences strategy and artificial intelligence drafting products. Beyond organic development, participation in the Vertex Ventures-led US$3.0m seed round of the autonomous research platform Drylab AI, and integration with the ASEAN IP Cooperation further reinforce its ecosystem footprint.

Governance Drags Offset by Strengthening Data Moats: The pvtIQ Fundamental SmartScore© improved, led by Growth and Management after strategic talent acquisitions and a new data partnership, although Governance remains constrained by limited public disclosure of financial reporting and senior leadership. The pvtIQ Alt-Data SmartScore© also strengthened. Strong Product Affinity and Authority dimensions reflect consistent user satisfaction and high search engine visibility, while Socials remains the weakest dimension despite improving.


PatSnap: Deepening the AI-Native Transition into Agentic Workflows (Update)